Insider Trading May 13, 2026 04:54 PM

Vita Coco COO Executes $2.25 Million Stock Sale via Rule 10b5-1 Plan

Jonathan Burth disposes of 30,000 shares following an option exercise as the company reports strong Q1 2026 results.

By Avery Klein COCO

Jonathan Burth, the Chief Operating Officer of Vita Coco Company, Inc. (NASDAQ: COCO), has completed a sale of 30,000 shares of common stock. The transaction, which took place on May 12, 2026, was conducted under a Rule 10b5-1 trading plan and resulted in proceeds of approximately $2.25 million. The shares were sold at a price point of $75.00 per share, a level sitting just below the stock's 52-week high of $75.64. This divestment occurs amid a period of significant share price appreciation for the company, with COCO having climbed 125% over the last year and posted a year-to-date gain of 41%, currently trading at $74.77.

Vita Coco COO Executes $2.25 Million Stock Sale via Rule 10b5-1 Plan
COCO

Key Points

  • COO Jonathan Burth sold 30,000 shares at $75.00 per share via a 10b5-1 plan.
  • Vita Coco outperformed Q1 2026 expectations with $180 million in revenue and $0.50 EPS.
  • The stock has seen a 125% increase over the past year.

Executive Transaction Details

The recent transaction by Chief Operating Officer Jonathan Burth involved both the acquisition and subsequent sale of company equity. Prior to the sale of the 30,000 shares, Mr. Burth exercised non-qualified stock options that were fully vested and ready for exercise. These options were acquired at an exercise price of $10.178 per share, representing a total cost of $305,340 for the acquisition portion of the transaction.

Following these movements in his holdings, Mr. Burth maintains a direct ownership of 57,910 shares of Vita Coco common stock. In addition to these direct holdings, he retains various non-qualified stock options that grant him the right to purchase an aggregate of 249,867 additional shares. The exercise prices for these remaining options range from $10.178 to $33.36 per share. These options are subject to different vesting structures, including some that are fully vested, others tied to annual installments, and certain holdings contingent upon performance conditions. The expiration dates for this suite of options extend as far as March 2035.


Financial Context and Market Performance

The sale occurs against a backdrop of robust financial performance for Vita Coco. During the first quarter of 2026, the company reported results that exceeded market expectations on both the top and bottom lines. The company posted earnings per share (EPS) of $0.50, which was a 56.25% surprise compared to the anticipated $0.32. Furthermore, quarterly revenue reached $180 million, outperforming the projected $147.39 million by 22.12%. This strong start to the year has contributed to heightened investor interest and has led some analysts to consider potential adjustments to their future outlooks.

Key Analysis Points

  • Significant Equity Appreciation: The stock has experienced a massive upward trend, with a 125% increase over the past year and a 41% gain since the start of the year.
  • Strong Earnings Momentum: Vita Coco's ability to significantly beat both revenue and EPS forecasts in Q1 2026 highlights operational strength relative to market projections.
  • Rule 10b5-1 Execution: The use of a pre-set trading plan for the $2.25 million sale provides a structured mechanism for executive liquidity.

These factors primarily impact the consumer goods and equity markets, as large-scale insider transactions and significant earnings beats can influence broader sector sentiment and valuation models.


Risk Factors and Uncertainties

  • Valuation Concerns: With a P/E ratio of 47.77, there are indications that the stock may be overvalued relative to fair value estimates, which could impact consumer discretionary sector stability.
  • Market Volatility: While recent performance has been strong, the high level of recent appreciation and proximity to 52-week highs introduces potential volatility for investors in the beverage and consumer sectors.

Risks

  • Valuation risk as the stock trades at a P/E of 47.77 and may be considered overvalued.
  • Market sensitivity to recent rapid price surges.

More from Insider Trading

Liquidity Services Director Executes Stock Sale Amid Recent Price Volatility May 13, 2026 Diodes Incorporated CTO Executes Stock Sale Amidst Leadership Transition and Recent Financial Performance May 13, 2026 Penguin Solutions Director Executes Stock Dispositions Worth Over $537,000 May 13, 2026 Halozyme Therapeutics CEO Executes Planned Stock Sale Following Q1 Earnings Beat May 13, 2026 Xometry Chief Sales Officer Executes Stock Sales Totaling Over $611,000 May 13, 2026